ALVO
Alvotech
ALVO has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ALVO overall, supported by stronger fundamentals.
ALVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Weak |
ALVO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALVO PE Valuation
ALVO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 19x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ALVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect ALVO to return to profit, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ALVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q2 2026 | -$0.63 | -432% |
| Q1 2026 | -$0.34 | -200% |
| Q4 2025 | $0.00 | +$0.83 |
| Q3 2025 | $0.21 | +$1.86 |
| Q3 2024 | -$1.65 | +$0.56 |
| Q1 2021 | -$4.90 | -$4.07 |
| Q4 2020 | -$0.69 | +$0.19 |
ALVO has swung to a loss: it lost $0.63 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ALVO on earnings quality, reporting a profit while its opponent remains loss making.
ALVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $105.8M | -39% |
| Q1 2026 | $105.9M | -20% |
| Q4 2025 | $166.4M | +10% |
| Q3 2025 | $114M | +11% |
| Q2 2025 | $173.2M | -13% |
| Q1 2025 | $132.8M | +260% |
| Q4 2024 | $151.2M | +183% |
| Q3 2024 | $102.9M | +478% |
ALVO's revenue has slid since its 2024 peak: $106M last quarter, down 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -22 points |
| Q1 2026 | 9.1% | +1.1 points |
| Q4 2025 | 29% | +20 points |
| Q3 2025 | 1.2% | -11 points |
| Q2 2025 | 10% | -36 points |
| Q1 2025 | 8% | +139 points |
| Q4 2024 | 8.9% | +157 points |
| Q3 2024 | 12% | +511 points |
ALVO's operating margin was −11% last quarter, down 22 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ALVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ALVO on profitability, with a higher operating margin.
ALVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$47.7M | -213% |
| Q1 2026 | -$106.6M | -$95.8M |
| Q4 2025 | -$71.5M | -$1.2M |
| Q3 2025 | -$74.5M | +$11M |
| Q2 2025 | $42.1M | +$99.8M |
| Q1 2025 | -$10.8M | +$69.2M |
| Q4 2024 | -$70.3M | +$7.4M |
| Q3 2024 | -$85.5M | +$38.4M |
ALVO has burned cash in almost every quarter: −$300M over the past year, against −$124M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ALVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +26.5M shares |
| 1 year | +14% | +43.4M shares |
| 3 years | +56% | +128M shares |
| 5 years | +1042% | +326M shares |
| Available history | +46% | +113M shares |
ALVO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ALVO hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 200.4x | High |
| Q1 2026 | 23.3x | High |
| Q4 2025 | 8.8x | High |
| Q3 2025 | 11.3x | High |
| Q2 2025 | 5.4x | High |
| Q1 2025 | 8.6x | High |
| Q3 2022 | 8.1x | High |
ALVO's net debt is more than 20 years of its operating earnings (EBITDA), up from 5.4 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ALVO on leverage, with a lower net debt burden relative to earnings.
ALVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.9 | Neutral |
| Stochastic | 40.7 | Neutral |
ALVO's weekly RSI is 50 (neutral) and its Stochastic is 41 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALVO PE vs Healthcare Sector
| Metric | ALVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ALVO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ALVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.09 | 8.3% below |
| 20 week MA | $4.60 | 1.5% above |
| 50 week MA | $4.33 | 7.9% above |
| 100 week MA | $6.96 | 33% below |
| 200 week MA | $9.28 | 50% below |
ALVO's trend is mixed: it's above two of its five weekly moving averages, and 50% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALVO on trend strength, trading above more of its moving averages.
ALVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $9.70 | $10.0 | +3.1% |
| 2023 | $10.0 | $11.5 | +15% |
| 2024 | $11.5 | $12.7 | +10% |
| 2025 | $12.7 | $5.26 | -58% |
| 2026 YTD | $5.26 | $4.67 | -11% |
ALVO has finished higher in three of the last four years. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALVO on returns for 2026, with the stronger performance.